Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...

As of Tuesday's close, Lilly's stock is down 4.6% in 2025, while the S&P 500 SPX has risen 9.5% and the iShares U.S. Pharmaceuticals exchange-traded fund IHE has risen 6.6%.